David S. Kinard - 01 Mar 2023 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Executive Vice President, Human Resources, Corporate Affairs and Administration
Signature
/s/ Catherine S. Powell, as Attorney-in-Fact for David S. Kinard
Issuer symbol
ELAN
Transactions as of
01 Mar 2023
Net transactions value
-$39,056
Form type
4
Filing time
03 Mar 2023, 20:07:05 UTC
Previous filing
03 Mar 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Tax liability $27,947 -2,482 -2.6% $11.26 92,860 01 Mar 2023 Direct F1, F2
transaction ELAN Common Stock Award $0 +22,270 +24% $0.000000 115,130 01 Mar 2023 Direct F3
transaction ELAN Common Stock Tax liability $11,109 -1,009 -0.88% $11.01 113,541 02 Mar 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option (right to buy) Award $0 +50,863 $0.000000 50,863 01 Mar 2023 Common Stock 50,863 $11.26 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan.
F2 Includes 699 shares acquired under Elanco Animal Health Inc.'s Employee Stock Purchase Plan between September 30, 2022 and December 30, 2022.
F3 Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2023, one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.
F4 Balance reflects 580 fewer shares due to an error in the number of shares previously reported as forfeited in a prior Form 4.
F5 Grant of stock options vesting as follows: one-third vesting on March 1, 2024, one-third vesting on March 1, 2025, and the remaining vesting on March 1, 2026.

Remarks:

Executive Vice President, Human Resources, Corporate Affairs and Administration